03671nam 2200769z- 450 991055738060332120231214132940.0(CKB)5400000000042093(oapen)https://directory.doabooks.org/handle/20.500.12854/76940(EXLCZ)99540000000004209320202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierSmall Cell Lung Cancer: A New Era Is Beginning?Basel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 electronic resource (150 p.)3-0365-2301-4 3-0365-2302-2 Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody–drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques.Small Cell Lung CancerMedicinebicsscimmune checkpoint inhibitorsextensive-stage small cell lung cancernivolumabipilimumabpembrolizumabatezolizumabdurvalumabchemotherapysmall-cell lung cancerlobectomypneumonectomyradiotherapymultimodal treatmentimmunotherapySCLCPARPDDRICBsynthetic lethalitySLFN11STINGpathology and classification of SCLCbiology of SCLCimmune-checkpoint inhibitors in SCLCsmall cell lung cancerImmunotherapyextensive diseaselurbinectedingene pathwaypathobiologytargeted therapycirculating tumor cellsprognostic biomarkertargeted agentsMedicineMorabito Alessandroedt1326702Rolfo ChristianedtMorabito AlessandroothRolfo ChristianothBOOK9910557380603321Small Cell Lung Cancer: A New Era Is Beginning3037687UNINA